Virtual Library

Start Your Search

R. Bruns



Author of

  • +

    Best abstracts selected from submissions 3 (ID 3)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 1
    • +

      OA06 - Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: (ID 140)

      16:20 - 17:00  |  Author(s): R. Bruns

      • Abstract

      Background:
      The MET pathway is frequently deregulated in human cancer, leading to dependency on MET signaling and hence this represents a potential therapeutic target in non-small cell lung cancer (NSCLC). MET alterations include MET exon 14-skipping mutations (METex14+) and MET amplification (METamp); these occur in ~3% and 0.4

  • +

    Best abstracts selected from submissions 7 (ID 5)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
    • +

      OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (ID 67)

      16:20 - 17:00  |  Author(s): R. Bruns

      • Abstract
      • Slides

      Background:
      Non-small cell lung cancer (NSCLC) can acquire resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs) via MET activation; dual MET/EGFR inhibition may have potential in EGFR TKI-resistant NSCLC. Tepotinib is a potent, selective MET TKI. We report randomized phase 2 data from a phase 1b/2 signal detection trial of tepotinib+gefitinib vs chemotherapy (pemetrexed + cisplatin/carboplatin) in patients with MET+/EGFR+T790M- NSCLC (NCT01982955).


      Method:
      Asian patients with advanced MET+ (IHC2+, IHC3+, gene amplification) NSCLC, acquired resistance to 1st-line EGFR TKI and ECOG performance status 0

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.